ZNTL logo

Zentalis Pharmaceuticals (ZNTL) Company Overview

Profile

Full Name:

Zentalis Pharmaceuticals, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

April 3, 2020

Indexes:

Not included

Description:

Zentalis Pharmaceuticals is a biopharmaceutical company focused on developing innovative cancer treatments. They create targeted therapies to improve patient outcomes and address unmet medical needs in oncology. Their research aims to advance new medicines that can effectively fight various types of cancer.

Events Calendar

Earnings

Next earnings date:

Feb 27, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 30, 25 Wells Fargo
Equal-Weight
Jan 29, 25 HC Wainwright & Co.
Buy
Jan 28, 25 UBS
Neutral
Nov 15, 24 HC Wainwright & Co.
Buy
Nov 15, 24 Guggenheim
Buy
Sep 16, 24 Oppenheimer
Outperform
Aug 12, 24 Wedbush
Neutral
Aug 12, 24 HC Wainwright & Co.
Buy
Jun 20, 24 UBS
Neutral
Jun 18, 24 Wells Fargo
Equal-Weight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Levi & Korsinsky Reminds Zentalis Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZNTL
Levi & Korsinsky Reminds Zentalis Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZNTL
Levi & Korsinsky Reminds Zentalis Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZNTL
ZNTL
accessnewswire.comFebruary 5, 2025

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis Pharmaceuticals, Inc.") (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis issued a press release on January 28, 2025, "announc[ing] a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
ZNTL
accessnewswire.comFebruary 5, 2025

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company")(NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Zentalis Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - ZNTL
Zentalis Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - ZNTL
Zentalis Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - ZNTL
ZNTL
accessnewswire.comFebruary 4, 2025

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis Pharmaceuticals, Inc.") (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis issued a press release on January 28, 2025, "announc[ing] a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
ZNTL
prnewswire.comFebruary 4, 2025

NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

ZNTL STOCK ALERT: Levi & Korsinsky Notifies Zentalis Pharmaceuticals, Inc. Investors of an Ongoing Investigation
ZNTL STOCK ALERT: Levi & Korsinsky Notifies Zentalis Pharmaceuticals, Inc. Investors of an Ongoing Investigation
ZNTL STOCK ALERT: Levi & Korsinsky Notifies Zentalis Pharmaceuticals, Inc. Investors of an Ongoing Investigation
ZNTL
accessnewswire.comFebruary 4, 2025

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis Pharmaceuticals, Inc.") (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis issued a press release on January 28, 2025, "announc[ing] a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026.

ZNTL ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Zentalis Pharmaceuticals, Inc. Shareholders Who Lost Money
ZNTL ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Zentalis Pharmaceuticals, Inc. Shareholders Who Lost Money
ZNTL ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Zentalis Pharmaceuticals, Inc. Shareholders Who Lost Money
ZNTL
accessnewswire.comFebruary 1, 2025

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis Pharmaceuticals, Inc.") (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis issued a press release on January 28, 2025, "announc[ing] a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
ZNTL
accessnewswire.comFebruary 1, 2025

NEW YORK CITY, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
ZNTL
accessnewswire.comJanuary 29, 2025

NEW YORK CITY, NY / ACCESS Newswire / January 29, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
ZNTL
globenewswire.comJanuary 29, 2025

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC)

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
ZNTL
globenewswire.comJanuary 28, 2025

Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2

FAQ

  • What is the ticker symbol for Zentalis Pharmaceuticals?
  • Does Zentalis Pharmaceuticals pay dividends?
  • What sector is Zentalis Pharmaceuticals in?
  • What industry is Zentalis Pharmaceuticals in?
  • What country is Zentalis Pharmaceuticals based in?
  • When did Zentalis Pharmaceuticals go public?
  • Is Zentalis Pharmaceuticals in the S&P 500?
  • Is Zentalis Pharmaceuticals in the NASDAQ 100?
  • Is Zentalis Pharmaceuticals in the Dow Jones?
  • When was Zentalis Pharmaceuticals's last earnings report?
  • When does Zentalis Pharmaceuticals report earnings?
  • Should I buy Zentalis Pharmaceuticals stock now?

What is the ticker symbol for Zentalis Pharmaceuticals?

The ticker symbol for Zentalis Pharmaceuticals is NASDAQ:ZNTL

Does Zentalis Pharmaceuticals pay dividends?

No, Zentalis Pharmaceuticals does not pay dividends

What sector is Zentalis Pharmaceuticals in?

Zentalis Pharmaceuticals is in the Healthcare sector

What industry is Zentalis Pharmaceuticals in?

Zentalis Pharmaceuticals is in the Biotechnology industry

What country is Zentalis Pharmaceuticals based in?

Zentalis Pharmaceuticals is headquartered in United States

When did Zentalis Pharmaceuticals go public?

Zentalis Pharmaceuticals's initial public offering (IPO) was on April 3, 2020

Is Zentalis Pharmaceuticals in the S&P 500?

No, Zentalis Pharmaceuticals is not included in the S&P 500 index

Is Zentalis Pharmaceuticals in the NASDAQ 100?

No, Zentalis Pharmaceuticals is not included in the NASDAQ 100 index

Is Zentalis Pharmaceuticals in the Dow Jones?

No, Zentalis Pharmaceuticals is not included in the Dow Jones index

When was Zentalis Pharmaceuticals's last earnings report?

Zentalis Pharmaceuticals's most recent earnings report was on Nov 12, 2024

When does Zentalis Pharmaceuticals report earnings?

The next expected earnings date for Zentalis Pharmaceuticals is Feb 27, 2025

Should I buy Zentalis Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions